Browse > Article

Bioequivalence Assessment of Domperidone Maleate Tablets in Healthy Korean Volunteers  

Kim, Sung-Chull (College of Pharmacy, Yeungnam University)
Lee, Jun-Woo (College of Pharmacy, Yeungnam University)
Yoo, An-Na (College of Pharmacy, Yeungnam University)
Chang, Hyun-Sung (College of Pharmacy, Yeungnam University)
Lee, Kyung-Hee (Yeungnam University Medical Center)
Park, Jong-Min (Yeungnam University Medical Center)
Nam, Doo-Hyun (College of Pharmacy, Yeungnam University)
Publication Information
Biomolecules & Therapeutics / v.11, no.2, 2003 , pp. 145-150 More about this Journal
Abstract
The bioequivalence of two tablet formulations of 12.72mg domperidone maleate (Sinil "$Perinal^{\circledR}$" tablets vs. Janssen Korea "Motilium-$M^{\circledR}$" tablets) was assessed in healthy Korean volunteers after oral administration in a randomized crossover study. Blood samples were collected at spccified time intervals, and plasma concentration was measured as the amount of domperidone base using a validated HPLC method. The pharmacokinetic parameters of $AUC_{0{\rightarrow}48},\; C_{max},\;T_{max}$ and $t_{1/2}$ were determined from plasma concentration-time profile of two formulations. Any significant statistical differences were not observed between these two formulations. On the evaluation of bioequivalence according to Korea Food and Drug Administration Guideline, 90％ confidence limits after logmithmic transformation fell within the acceptable range (log 0.8∼log 1.25). Based on these data, it can be concluded that two domperidone maleate tablets showed comparable pharmacokinetic profiles, which means that the Sinil "$Perinal^{\circledR}$" tablet is bioequivalent to the Janssen Korea ""Motilium-M$^{\circledR}$".
Keywords
domperidone; bioequivalence; pharmacokinetics; HPLC; $Perinal^{\circledR}$; Motilium-$M^{\circledR}$;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Srnit, M. J., Sutherland, F. C. Hundt, H. K, Swart, K. J., Hundt, A. F. and Els, J. (2002). Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the quanitation of clomperidone in human plasma. J. Chromatogr A 949, 6570
2 Lee, Y. J., Kim, Y. G., Lee, M. G., Chung, S. J., Lee. M. H. and Shim, C. K. (2000). Analysis of bioequivalent study using a log-transformed model, Yakhak Hoeji 44,308-314
3 MacGregor, E. A. (2001). Anti-emesis. Curr. Med. Res. Opin. 17, s22-s25   DOI   ScienceOn
4 Huang, Y.-C., Colaizzi, J. L., Bierman, R. H., Woestenborghs, R. and Heykants, J. J. P (1986). Pharmacokinetics and dose proportionality of domperidonc in healthy volunteers. J. Clin. Pharmacol. 26, 628-632   DOI
5 KFDA (2001). The guideline for bioequivalence test. Korea Food and Drug Administration Act No. 2001-57
6 Lacluron, P. M. and Leysen, J. E. (1979). Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem. Pharrnacol, 28, 2161-2165   DOI   ScienceOn
7 Brogden, R. N., Carmine, A. A., Heel, R. C., Speight, T. M. and Avery, G. S. (1982). Domperidone. Drugs 24, 360-400   DOI   ScienceOn
8 Wu, M.S., Gao, L, Cai, X. H., Wang, G. J. (2002). Determination of domperidonc in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacal. Sin. 23, 285-288
9 Yamamoto, K., Hagino, M., Kotaki, H. and Iga, T. (1998). Quantitativc determination or domperidone in rat plasma by highperformance liquid chromatography with fluorescence detection. J. Chromatogr. B 720,251-255   DOI   ScienceOn
10 Zavitsanos, A. P., MacDonald, C., Bassoo, E. and Gopaul, D. (1999). Determination of dompcridone in human serum and human breast milk by high-performance liquid chromatography-electrospray mass spectrometry. J. Chrornatogt: B 730, 924
11 Champion, M. C. (1988). Dornpcridone. Gen. Pharmacol. 19, 499-505   DOI   ScienceOn
12 Champion, M. C., Hartnett, M. and Yen, M. (1986). Domperidone, a new dopamine antagonist. CMAJ 135, 457-461
13 EMEA (2001). Guidance on the investigation of bioavailobility and bioequivalence, The European Agency for the Evaluation of Meclicinal Products
14 FDA (2001). Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation ancl Research (CDER)
15 Mitchelson, F. (1992). Pharmacological agents affecting emesis. Drugs 43, 295-315   DOI   ScienceOn
16 Heykants, J., Hendriks, R., Meulderrnans, W., Michiels, M., Scheygrond, H. and Reyntjens, H. (1981b) On the pharmacokinetics of dompericlone in animals and man. IV. The pharmacokinetics pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet, 6, 61-70   DOI
17 Heykants, J., Knacps, A, Meulderrnans, W. and Michiels, M. (1981a). On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of dompericlone in ruts and dogs. Age related absorption and passage through the blood brain barrier in rats. Eur. J. Drug Metab. Pharmacokinet. 6, 27-36.   DOI
18 Meulderrnans, W., Hurkrnans, R., Swysen, E., Hendrick, J., Michiels, M., Lauwers, W. and Heykants, J (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of dompericlone in rats, dogs and man. Eur. J. Drug Metab. Pharmacokinet. 6, 49-60   DOI
19 Michiels, M., Hendriks, R., and Heykants, J. (1981). On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur. J. Drug Metab. Pharmacokinet. 6, 37-48   DOI
20 Parfitt, K. (1999). Martindale. The complete drug reference. pp.1190-1191. Pharmaceutical Press. London. UK.
21 Shargel, L. and Yu, A. B. C. (1993). BioavaiIabiIity and bioequivalence, In Applied Biophannaceutics and Pharmacokinetics, 3rd ed., pp.193-223, Appleton & Lange, Norwalk, USA